Medline ® Abstract for Reference 99
of 'Juvenile myoclonic epilepsy'
99
TI
Outcome of lamotrigine treatment in juvenile myoclonic epilepsy.
AU
Bodenstein-Sachar H, Gandelman-Marton R, Ben-Zeev B, Chapman J, Blatt I
SO
Acta Neurol Scand. 2011 Jul;124(1):22-7. Epub 2011 Jan 6.
OBJECTIVES:
To determine the response rate of patients with juvenile myoclonic epilepsy (JME) to lamotrigine (LTG) and identify predictive factors for treatment response.
MATERIAL AND METHODS:
Medical records of 62 patients with JME were reviewed for demographic, clinical, and EEG parameters. We determined clinical response to LTG and compared LTG responders with non-responders.
RESULTS:
There were 35 LTG responders (56%) and 27 non-responders (44%). JME patients without generalized tonic clonic seizures (GTCS) responded better to LTG (P = 0.04). Valproic acid (VPA) failure because of adverse events rather than lack of efficacy (P = 0.069) and delay in diagnosis (P = 0.07) showed a tendency toward good response to LTG.
CONCLUSIONS:
LTG should be considered a drug of first choice for JME patients without GTCS. LTG as second-line treatment after VPA failure seems more appropriate for those patients whose reason for VPA failure is poor tolerability rather than lack of efficacy.
AD
Department of Neurology, Sheba Medical Center, Tel-Hashomer, Israel.
PMID